Bajaj Healthcare Ltd
Incorporated in 1993, Bajaj Healthcare Ltd manufactures a wide range of Active Pharmaceutical Ingredients and Formulations[1]
- Market Cap ₹ 1,512 Cr.
- Current Price ₹ 480
- High / Low ₹ 745 / 333
- Stock P/E 32.1
- Book Value ₹ 148
- Dividend Yield 0.21 %
- ROCE 11.4 %
- ROE 10.7 %
- Face Value ₹ 5.00
Pros
- Company has reduced debt.
Cons
- Stock is trading at 3.25 times its book value
- The company has delivered a poor sales growth of 5.76% over past five years.
- Company has a low return on equity of 4.15% over last 3 years.
- Dividend payout has been low at 3.71% of profits over last 3 years
- Company has high debtors of 169 days.
- Promoter holding has decreased over last 3 years: -8.11%
- Working capital days have increased from 55.6 days to 140 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare BSE SmallCap BSE Allcap
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
205 | 218 | 223 | 231 | 327 | 370 | 410 | 657 | 680 | 646 | 473 | 543 | 559 | |
186 | 189 | 193 | 200 | 288 | 327 | 362 | 521 | 561 | 534 | 397 | 460 | 477 | |
Operating Profit | 19 | 29 | 30 | 31 | 39 | 43 | 48 | 136 | 119 | 112 | 76 | 83 | 82 |
OPM % | 9% | 13% | 14% | 13% | 12% | 12% | 12% | 21% | 17% | 17% | 16% | 15% | 15% |
0 | 0 | 0 | 2 | 2 | 1 | 7 | 7 | 1 | -19 | -105 | 16 | 17 | |
Interest | 7 | 8 | 8 | 8 | 8 | 8 | 7 | 8 | 13 | 18 | 30 | 28 | 25 |
Depreciation | 9 | 9 | 9 | 11 | 11 | 11 | 12 | 16 | 18 | 17 | 28 | 28 | 27 |
Profit before tax | 3 | 12 | 14 | 14 | 23 | 24 | 36 | 119 | 90 | 58 | -86 | 43 | 47 |
Tax % | 40% | 37% | 39% | 43% | 33% | 33% | 30% | 30% | 20% | 25% | -3% | 7% | |
2 | 8 | 8 | 8 | 15 | 16 | 25 | 83 | 71 | 43 | -84 | 40 | 44 | |
EPS in Rs | 2.19 | 8.34 | 3.04 | 2.83 | 5.50 | 5.91 | 9.14 | 30.11 | 25.87 | 15.59 | -30.36 | 12.51 | 14.00 |
Dividend Payout % | 0% | 0% | 0% | 0% | 5% | 0% | 0% | 5% | 6% | 6% | -3% | 8% |
Compounded Sales Growth | |
---|---|
10 Years: | 10% |
5 Years: | 6% |
3 Years: | -7% |
TTM: | 17% |
Compounded Profit Growth | |
---|---|
10 Years: | 18% |
5 Years: | 10% |
3 Years: | -18% |
TTM: | 52% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 15% |
3 Years: | 10% |
1 Year: | 35% |
Return on Equity | |
---|---|
10 Years: | 13% |
5 Years: | 13% |
3 Years: | 4% |
Last Year: | 11% |
Balance Sheet
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 2 | 2 | 7 | 7 | 7 | 7 | 14 | 14 | 14 | 14 | 14 | 16 |
Reserves | 28 | 78 | 82 | 92 | 107 | 122 | 164 | 245 | 315 | 354 | 265 | 450 |
72 | 70 | 81 | 75 | 87 | 81 | 91 | 181 | 257 | 415 | 333 | 223 | |
43 | 38 | 39 | 45 | 68 | 57 | 74 | 86 | 136 | 115 | 154 | 144 | |
Total Liabilities | 145 | 189 | 209 | 219 | 268 | 267 | 343 | 526 | 721 | 898 | 765 | 833 |
56 | 108 | 130 | 128 | 127 | 128 | 162 | 208 | 270 | 366 | 253 | 238 | |
CWIP | 3 | 1 | 1 | 0 | 2 | 1 | 5 | 57 | 52 | 22 | 7 | 3 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 0 |
87 | 79 | 78 | 91 | 140 | 137 | 170 | 260 | 399 | 510 | 506 | 591 | |
Total Assets | 145 | 189 | 209 | 219 | 268 | 267 | 343 | 526 | 721 | 898 | 765 | 833 |
Cash Flows
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
17 | 28 | 25 | 22 | 17 | 25 | 21 | 44 | 1 | -22 | 92 | 22 | |
-9 | -17 | -31 | -8 | -12 | -13 | -28 | -109 | -75 | -93 | -11 | -15 | |
-8 | -11 | 5 | -13 | 2 | -13 | 3 | 75 | 62 | 131 | -97 | -6 | |
Net Cash Flow | 1 | -0 | -0 | 0 | 7 | -0 | -4 | 10 | -12 | 16 | -16 | 0 |
Ratios
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 98 | 86 | 70 | 83 | 90 | 77 | 88 | 55 | 99 | 110 | 139 | 169 |
Inventory Days | 51 | 50 | 56 | 45 | 57 | 45 | 54 | 94 | 143 | 199 | 206 | 206 |
Days Payable | 68 | 63 | 46 | 51 | 74 | 45 | 80 | 67 | 94 | 81 | 128 | 122 |
Cash Conversion Cycle | 81 | 73 | 80 | 78 | 73 | 77 | 62 | 82 | 148 | 228 | 217 | 254 |
Working Capital Days | -25 | -11 | -17 | -4 | 0 | 12 | 24 | 34 | 40 | 27 | -0 | 140 |
ROCE % | 10% | 16% | 13% | 13% | 16% | 16% | 18% | 36% | 20% | 14% | 8% | 11% |
Documents
Announcements
-
Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015
4 Oct - CDSCO SEC recommended Phase III trials for Suvorexant (5mg,10mg,15mg,20mg); announced Oct 4, 2025.
-
Shareholder Meeting/Postal Ballot- Voting Results & Scrutinizer''s Report
29 Sep - 32nd AGM (26 Sep 2025): all 8 resolutions approved; final dividend declared.
-
Shareholder Meeting / Postal Ballot-Outcome of AGM
26 Sep - 32nd AGM on Sept 26, 2025: adopted FY2024-25 financials, declared final dividend, appointed/re-appointed directors and auditors.
- Closure of Trading Window 24 Sep
-
Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015- Updates
24 Sep - Clarified volume spike; no undisclosed material information or promoter/insider transactions.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
Business Overview:[1][2][3]
BHL is focused on development, supply, manufacturing of Amino Acids, Nutritional Supplements and Active Pharma Ingredients for Pharmaceutical, Nutraceuticals and Food industries. It manufactures active pharmaceutical ingredients and formulations in the form of tablets, capsules, powder, etc. for ~550+ clients, exporting bulk drugs to ~62+ countries in Europe, USA, Africa, Australia, etc.